HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opiate Addiction Remedy Claims Could Face FTC Substantiation Test

This article was originally published in The Rose Sheet

Executive Summary

The Council of Better Business Bureaus' investigative arm asks Opiate Freedom Center for evidence to substantiate ad claims including "Home Remedies for Opiate Withdrawal Symptom Relief" and supplements "developed to naturally replenish depleted nutrients during opiate detox and withdrawal."

You may also be interested in...



Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue

FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.

Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI

FDA and the Federal Trade Commission should bring immediate enforcement action against marketers of non-kratom dietary supplements promoted as opioid-withdrawal aids, says the Center for Science in the Public Interest in letters to the agency and commission Dec. 8. The nonprofit identified eight supplement products making opioid-withdrawal claims without sufficient science to support the statements.

Trump's Opioid Commission Asks FDA To Boost Post-Market Vigilance

Pharma is criticized for aggressive marketing, but the report also seeks industry help in research on innovative medication.

Related Content

Topics

UsernamePublicRestriction

Register

RS121304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel